Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Should l Buy ?
Source: Globenewswire
Sales Growth: Catheter Precision, Inc. reports that sales of its LockeT device for Q2 2025 are projected to be the highest ever, with a 200% increase compared to Q2 2024, and several hospitals are expected to place significant purchase orders by year-end.
Market Expansion: The company has received CE Mark approval for LockeT, allowing sales in Europe, and is actively seeking distributors in Italy, Spain, Portugal, and the UK to enhance product awareness and usage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
